Article Information
- Received January 4, 2011
- Accepted March 24, 2011
- Published online June 17, 2011.
Article Versions
- Earlier version (March 24, 2011 - 11:00).
- You are viewing the most recent version of this article.
Author Information
- Malin Darnell,
- Thomas Schreiter,
- Katrin Zeilinger,
- Thomas Urbaniak,
- Therese Söderdahl,
- Ingrid Rossberg,
- Birgitta Dillnér,
- Anna-Lena Berg,
- Jörg C. Gerlach and
- Tommy B. Andersson
- Drug Metabolism & Pharmacokinetics Centre of Excellence (M.D., T.B.A.) and Global Safety Assessment (T.Sö., B.D., A.-L.B.), AstraZeneca R&D, Mölndal, Sweden; Division of Experimental Surgery, Berlin Brandenburg Center for Regenerative Therapies, Charité Universitätsmedizin Berlin, Berlin, Germany (T.Sc., K.Z., T.U., I.R.); McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (J.C.G.); and Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (M.D., T.B.A.)
- Address correspondence to:
Tommy B. Andersson, DMPK Centre of Excellence, AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden. E-mail: tommy.b.andersson{at}astrazeneca.com
Part of this work was previously presented at the following meetings: Darnell M, Schreiter T, Söderdahl T, Rossberg I, Zeilinger K, Gerlach JC, and Andersson TB (2009) Cytochrome P450 induction in HepaRG cells cultured in a dynamic 3D bioreactor. Biotransformation and Disposition of Xenobiotics, 11th European Regional ISSX Meeting; 2009 May 17–20; Portugal, Lisbon. Official Journal of the International Society for the Study of Xenobiotics, Washington, DC; Darnell M, Schreiter T, Söderdahl T, Rossberg I, Zeilinger K, Gerlach JC, and Andersson TB (2009) Cytochrome P450 induction in HepaRG cells cultured in a dynamic 3D bioreactor. 2009 AAPS Annual Meeting and Exposition; 2009 Nov 8–12; Los Angeles, CA. American Association of Pharmaceutical Scientists, Arlington, VA.
